LINTEX
920106
LINGOOD
833284
NTGEC
870436
4
CG MED EQUIP.
838810
5
Jiayu Holding
300117
US Stock MarketDetailed Quotes
CTKB Cytek Biosciences
- 4.490
- -0.320-6.65%
Close Feb 28 16:00 ET
- 4.460
- -0.030-0.67%
Post 20:01 ET
575.16MMarket Cap-89.80P/E (TTM)
4.640High4.220Low1.24MVolume4.600Open4.810Pre Close5.55MTurnover1.13%Turnover RatioLossP/E (Static)128.10MShares9.32852wk High1.45P/B493.28MFloat Cap4.22052wk Low--Dividend TTM109.86MShs Float28.700Historical High--Div YieldTTM8.73%Amplitude3.800Historical Low4.482Avg Price1Lot Size
Cytek Biosciences Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 3.85%200.45M | -1.30%57.48M | 7.29%51.5M | -6.19%46.62M | 20.96%44.86M | 17.67%193.02M | 20.48%58.23M | 18.59%48M | 23.74%49.69M | 5.77%37.09M |
| Operating revenue | 3.85%200.45M | -1.30%57.48M | 7.29%51.5M | -6.19%46.62M | 20.96%44.86M | 17.67%193.02M | 20.48%58.23M | 18.59%48M | 23.74%49.69M | 5.77%37.09M |
| Cost of revenue | 6.89%89.35M | -5.40%23.82M | 8.03%22.5M | -1.63%21.18M | 36.12%21.85M | 32.55%83.59M | 32.82%25.19M | 52.93%20.82M | 38.04%21.53M | 7.81%16.05M |
| Gross profit | 1.54%111.11M | 1.83%33.65M | 6.72%29.01M | -9.68%25.44M | 9.39%23.01M | 8.37%109.43M | 12.51%33.05M | 1.18%27.18M | 14.66%28.16M | 4.27%21.04M |
| Operating expense | -4.11%131.63M | -7.59%30.67M | -1.03%33.25M | -8.92%33.96M | 1.65%33.75M | 33.56%137.27M | 13.30%33.19M | 31.75%33.6M | 46.51%37.29M | 47.33%33.2M |
| Selling and administrative expenses | -0.96%92.23M | -6.15%20.94M | 4.21%23.37M | -4.74%23.96M | 3.12%23.95M | 37.10%93.12M | 14.19%22.32M | 33.08%22.43M | 47.82%25.15M | 60.08%23.23M |
| -Selling and marketing expense | -0.07%49.11M | 2.71%11.87M | 2.92%12.43M | -14.61%12.27M | 12.54%12.54M | 47.90%49.15M | 28.04%11.56M | 37.07%12.08M | 70.41%14.37M | 60.13%11.15M |
| -General and administrative expense | -1.95%43.11M | -15.68%9.07M | 5.71%10.94M | 8.42%11.69M | -5.57%11.41M | 26.76%43.97M | 2.29%10.76M | 28.71%10.35M | 25.64%10.79M | 60.03%12.08M |
| Research and development costs | -10.76%39.4M | -10.54%9.72M | -11.54%9.88M | -17.59%10M | -1.78%9.8M | 26.66%44.15M | 11.51%10.87M | 29.14%11.17M | 43.86%12.14M | 24.29%9.97M |
| Operating profit | 26.30%-20.52M | 2,279.56%2.99M | 33.83%-4.25M | 6.57%-8.53M | 11.74%-10.73M | -1,443.51%-27.85M | -263.10%-137K | -572.06%-6.42M | -924.35%-9.13M | -415.99%-12.16M |
| Net non-operating interest income expense | 138.60%10.36M | 549.53%6.85M | 27.95%1.31M | 61.87%1.28M | -37.55%918K | 112.22%4.34M | -45.64%1.05M | 9.84%1.03M | 409.38%792K | 356.99%1.47M |
| Non-operating interest income | 61.55%10.36M | 324.86%6.15M | -11.65%1.43M | 17.90%1.42M | -36.58%1.36M | 38.84%6.41M | -44.86%1.45M | 2.40%1.62M | 207.16%1.2M | 11,805.56%2.14M |
| Non-operating interest expense | ---- | ---- | -80.00%119K | -67.24%134K | -34.47%441K | -19.51%2.07M | -42.65%394K | -8.32%595K | -36.79%409K | 14.07%673K |
| Other net income (expense) | -42.74%4.46M | -84.63%491K | 155.88%3.09M | -96.61%59K | -50.18%823K | 665.62%7.79M | 52.75%3.19M | 371.46%1.21M | 785.04%1.74M | 541.71%1.65M |
| Other non- operating income (expenses) | -42.74%4.46M | -84.63%491K | 155.88%3.09M | -96.61%59K | -50.18%823K | 665.62%7.79M | 52.75%3.19M | 371.46%1.21M | 785.04%1.74M | 541.71%1.65M |
| Income before tax | 63.72%-5.7M | 151.11%10.32M | 103.75%157K | -8.96%-7.19M | 0.52%-8.99M | -1,346.75%-15.71M | -0.07%4.11M | -326.22%-4.19M | -370.74%-6.6M | -173.69%-9.04M |
| Income tax | 108.99%320K | 148.85%680K | -134.52%-784K | 247.17%3.25M | -26.47%-2.82M | -190.93%-3.56M | -451.52%-1.39M | 913.84%2.27M | -215.74%-2.21M | -95.02%-2.23M |
| Net income | 50.44%-6.02M | 75.23%9.64M | 114.58%941K | -137.78%-10.43M | 9.37%-6.17M | -589.05%-12.15M | 48.01%5.5M | -497.05%-6.46M | -525.07%-4.39M | -215.43%-6.81M |
| Net income continuous Operations | 50.44%-6.02M | 75.23%9.64M | 114.58%941K | -137.78%-10.43M | 9.37%-6.17M | -589.05%-12.15M | 48.01%5.5M | -497.05%-6.46M | -525.07%-4.39M | -215.43%-6.81M |
| Minority interest income | 0 | 0 | ||||||||
| Net income attributable to the parent company | 50.44%-6.02M | 75.23%9.64M | 114.58%941K | -137.78%-10.43M | 9.37%-6.17M | -571.58%-12.15M | 55.94%5.5M | -487.52%-6.46M | -633.78%-4.39M | -236.81%-6.81M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | 0 | |||||||||
| Net income attributable to common stockholders | 50.44%-6.02M | 75.23%9.64M | 114.58%941K | -137.78%-10.43M | 9.37%-6.17M | -571.58%-12.15M | 55.94%5.5M | -487.52%-6.46M | -633.78%-4.39M | -236.81%-6.81M |
| Basic earnings per share | 44.44%-0.05 | 75.00%0.07 | 120.00%0.01 | -166.67%-0.08 | 0.00%-0.05 | -550.00%-0.09 | 33.33%0.04 | -600.00%-0.05 | -574.31%-0.03 | -150.00%-0.05 |
| Diluted earnings per share | 44.44%-0.05 | 75.00%0.07 | 120.00%0.01 | -166.67%-0.08 | 0.00%-0.05 | -550.00%-0.09 | 33.33%0.04 | -600.00%-0.05 | -574.31%-0.03 | -150.00%-0.05 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |
Trending Stocks
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum
Moo Earnings
Jan 24 10:26
TSLA earnings preview: Grab rewards by guessing the opening price!